|
HTS Gene expression / SNP analysis
|
Early prediction of drug induced organ-specific toxicity. Toxicogenomics analysis of tissue- and organ-specific gene markers on nanocapillary HTS QRT-PCR panels. Expression of 56 genes are followed after in vivo administration of drugs in mouse liver heart, brain and kidney.
Avidin uses the high - throughput nanocapillary real-time PCR technology for SNP analysis (Applied Biosystems) and for gene expression analysis (BioTrove) for in-house developments and for service. The technology merges the high-throughput of DNA microarrays with the sound characteristics of QRT-PCR, therefore ideal for genomics screenings. The nanotiter plate consists of 3072 through-holes grouped in 48 subarrays of 64 through-holes. Each through-hole consists of an independent 33 nL PCR assay, thus enabling a large number of PCR to be made simultaneously on hundreds of samples.|
Cancer
|
Researchers at Avidin have synthesized analogues of novel Immune Modulatory Drugs (IMIDs) which may have benefits over the current treatments for multiple myeloma (MM), leukemias and other cancers.
In this project Avinomid develops lipid-based drugs for glioma. Lipid-based anti-cancer drugs are neither in the process of development nor in the market at present.
Avidin has discovered in collaboration with others cytoprotective compounds with a novel chemical structure scaffold. After chemical optimization and SAR analysis Q-50 was selected as the lead-compound for cardiovascular and neuroprotective indications.| Avidin patented anti-inflammatory drug candidates |
| Avidin submitted a patent application on novel natural compound analogues which may have potential applications in arthritis, Crohn-disease, psoriasis and other inflammatory diseases. |
| Avidin patented multifunctional kinolols |
| Avidin submitted a patent application on novel quinoline analogues which may have potential applications in anxiety disorders and Alzheimer’s disease (AD). The IP held by Avidin on the novel structure and its application is valuable, offering the possibility of widening the application of the drug candidate. |